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Abstract 
The master’s thesis study investigates the role of biomolecules in Alzheimer’s disease. 
Alzheimer’s disease is caused by amyloid plaques and neurofibrillary tangles. The major cause of 
amyloid plaques is the aggregation of 1-42 amino acid peptide (abeta) fragment of the amyloid 
precursor protein. Neurofibrillary tangles on the other hand, are caused predominantly by the 
aggregation of microtubule binding hexapeptide (VQIVYK) region of the tau protein. The plaques 
and tangles ultimately cause neuronal cell toxicity, leading to Alzheimer’s disease. Several factors 
are known to cause abeta and tau aggregation. Here in this study, we investigate the effect of 
biomolecules on the aggregation formation of abeta and tau peptides, and test the potential of 
macromolecules, small molecules, and nanotherapeutics on the inhibition of abeta and tau peptides 
aggregation. The objective of the thesis study is achieved by investigating the role of (i) 
glycosaminoglycans (ii) extracellular enzymes transglutaminase and lysyl oxidase, and (iii) 
cerebral proteins transferrin and human albumin in Alzheimer’s causing peptides abeta and tau 
aggregation and toxicity. Characterization tools used for this study include biochemical assays, 
transmission electron microscopy, confocal microscopy, atomic force microscopy, dynamic light 
scattering, and cellular assays. The thesis study reveals that, glycosaminoglycans, and extracellular 
enzymes promote the aggregation of tau and abeta peptides, while cerebral proteins prevent the 
aggregation. Further, results show that the effect of biomolecules mediated Alzheimer’s peptide 
aggregation and could be inhibited in the presence of macromolecules, small molecules, and 
nanoformulated cerebral proteins.  
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Chapter 1: Introduction 
1.1 Introduction 
Alzheimer’s disease (AD) is a neurological disorder that causes dementia; it affects 10% of the 
population age over 60 [1-2]. It is characterized by the presence of two abnormal proteins; 
extracellular amyloid plaques and intracellular neurofibrillary tau tangles in the brain [3-6]. Tau 
proteins consist of 441 amino acids with a microtubule binding region, that contains four repeated 
peptide units [7]. The hexapeptide repeats VQIVYK and VQIINK are found in the carboxyl region 
of the tau protein; they form beta sheets, aggregates, and fibril structure that resemble tau 
aggregation in vitro [8-11]. Amyloid-β (Aβ) is formed by cleavage of amyloid precursor protein 
(APP) by β-secretase and ϒ-secretase that are deposited in the cerebrospinal fluid (CSF) and blood 
[12]. The two main components of the Aβ peptide are Aβ (1-40) and Aβ (1-42) depending on their 
sequence.  
Several factors contribute to Alzheimer’s disease progression. Among them, extracellular 
biomolecules like glycosaminoglycans (GAGs) and enzymes like transglutaminase (TG) and lysyl 
oxidase (LOX), HSA been shown to co-localize and promote Aβ aggregation by catalyzing the 
crosslinking of Aβ and tau proteins leading to AD [13-14]. On the other hand, some plasma and 
cerebrospinal fluid proteins like transferrin (Tf) and human serum albumin (HSA) has been known 
to bind to Aβ in blood to prevent the deposition of Aβ plaques in brain (15-16). Due to the critical 
role of abeta and tau aggregation in AD, over the years several therapeutic approaches have been 
used to inhibit tau and Aβ aggregations [17-19]. Approaches include the application of small 
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molecules components [20-21], macromolecules [22-24], ligands based nanoparticles [25-26], and 
Aβ vaccines [27].  
Although previous studies report the role of biomolecules in Alzheimer’s disease, Alzheimer’s 
causing protein aggregation studies in the presence of biomolecules in vitro, hasn’t been explored 
in detail yet. In this thesis study, role of biomolecules glycosaminoglycans, extracellular enzymes, 
and cerebral protein on Alzheimer’s protein aggregation in vitro, is studied in detail. In addition, 
macromolecules, small molecules, and nanotechnological mediated therapeutic approaches for the 
inhibition of biomolecules mediated protein aggregation also studied briefly. The characterization 
tests that are used for this study include thioflavin-T and thioflavin-S, turbidity assays, dynamic 
light scattering, confocal microscopy, transmission electron microscopy, atomic force microscopy, 
and cellular assays. The thesis study could help new avenues for treating Alzheimer’s by targeting 
the biomolecules that promote protein aggregation during the disease.  
1.2 Research Objectives 
The overall goal of the thesis study is to investigate the role of biomolecuels on Alzhimer’s protein 
aggregation. The research objectives of this thesis are described in the following specific aims: 
Specific Aim1: Study the role of Glycosaminoglycans in Alzheimer’s protein aggregation.  
Specific Aim2: Study the role of extracellular enzymes in Alzheimer’s disease. 
Specific Aim 3: Study the role of cerebral proteins in Alzheimer’s disease.  
1.3 Thesis Organization 
This thesis is organized into seven chapters. Chapter 2 is a general background of Alzheimer’s 
disease and protein aggregation, as well as approaches used to characterize the aggregation. 
Potential drug therapeutics approaches for treating Alzheimer’s are also briefly reviewed. The 
intention of the background is to provide the context for the motivation and goals of this work and 
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to include an outline of the specific objectives of this work. Chapter 3 investigates the role of 
glycosaminoglycans on tau peptide aggregation, and Chapter 4 is a paper published in biopolymers 
that addresses the effect of cationic polymers on tau aggregation. Chapter 5 is a study on the role 
of extracellular enzymes on Alzheimer’s protein aggregation, while Chapter 6 investigates the role 
of cerebral proteins on abeta aggregation. Finally, Chapter 7 includes general conclusions and a 
summary of the contributions of this work, and future directions. 
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Chapter 2: Background and Literature Review 
2.1 Alzheimer’s Disease 
Alzheimer’s disease (AD) is a neurodegenerative disorder that causes dementia because of the 
continuous neuronal loss in brain [1]. It was statistically shown that 35.6 million people have AD; 
also, this estimation is said to double every 20 years [1, 2]. The treatments for AD are limited, 
short-term, and expensive ($604 billion in 2010) [3-7]. Moreover, the extracellular amyloid-beta 
(Aβ) plaques and intracellular hyperphosphorylated neurofibrillary tau tangles (NFTs) are the two 
hallmarks of AD [8, 9]. Also, the soluble building blocks of the Aβ and tau plaques and tangles 
respectively influence each other [10]. It was shown by experimental studies that injecting a mouse 
with Aβ into the brain increased the formation of tangles [11]. Another experiment conducted on 
mice with tau deficiency reveals that the effect of Aβ plaques was ameliorated, indicating the 
interplay between the two proteins [12]. Figure 2.1 depicts the signaling between abeta and tau.  
 
 
 
 
 
Figure 2.1: Signaling from Aβ through Tau in AD [10] 
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2.2 Alzheimer’s Disease-causing proteins 
    2.2.1 Tau protein aggregation and AD 
Tau protein is composed of microtubules (MT) binding domain that hold the carboxy- terminal 
(C-terminal), the proline region, and the acidic amino acid region [13, 14]. The microtubules 
binding domain in the tau protein stabilizes microtubules in neurons of healthy people [13, 14]. 
Whereas in AD patients, tau proteins hyper phosphorylate, aggregate, and misfold into 
neurofibrillary tangles during AD [14, 15]. These aggregates destabilize microtubules, which lead 
to deficiency in the metabolism of the proteins and synaptic malfunctioning [16, 17]. NFTs can’t 
be discarded and degraded by the neurons, so they will continuously come together and increase 
in the cytoplasm. It was proven that NFTs go through a specific pathway in AD patients [18-20]. 
First, tau proteins detach from MT for different reasons (phosphorylation, dephosphorylation, and 
tau gene mutation) [14]. Then, in the pretangle phase (pathogenic phase), tau proteins misfold and 
form nonfibrillary tau deposits (soluble). Additionally, these pretangles can’t be detected by β 
sheet dyes [21-23]. The second phase is the NFT formation, tau proteins start to aggregate which 
will cause the dendrites to shrink (shorten). Neuronal cells can survive for years before they get 
completely affected by tau aggregation and die. Also, the number of NFTs is connected to the 
severity or level of AD (dementia) [24]. Lastly, the ghost tangles phase, where the tangles become 
extracellular after cell death of neurons and the neuronal abrasions become more visible [15, 24, 
25]. Figure 2.2 illustrates the aggregation of tau and abeta during AD.  
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Figure 2.2: Aggregation of Tau and Aβ proteins in AD [25] 
 
2.2.2. Amyloid-beta and Alzheimer’s disease  
Senile plaques found in the brain of AD patients are composed of 39-42 residues of Aβ peptides 
[26-28]. Normally, Aβ peptides are the products of amyloid β protein precursor (APP) metabolism 
reaction [29, 30]. Whereas in AD patients, APP is cleaved by β-secretase and ϒ-secretase 
(proteolysis) which will increase the production of Aβ peptides [26, 27, 31-33]. Also, several beta 
fragments are generated during proteolysis process (Aβ 1-42 and Aβ 1-40), but it has shown that 
Aβ (1-42) peptides are found at higher concentrations in Aβ plaques [26, 34]. Then, Aβ peptides 
aggregate and fold into Aβ fibrils [35-37] that accumulate into Aβ plaques [38]. Furthermore, it 
was previously shown that Aβ fibrils are cytotoxic to cells [39, 40] and lead to neuronal disturbance 
(main cause of dementia) [37, 39, 41, 42]. Figure 2.3 illustrates the abeta formation in AD patients.  
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Figure 2.3: Formation of Aβ plaques in AD patients [43] 
 
2.3. Extracellular biomolecules and Alzheimer’s disease (AD) 
 2.3.1 Glycosaminoglycans (GAGs) and AD 
Proteoglycans (PGs) are proteins that are composed of GAGs side chains [44]. GAGs are long, 
linear, and heterogeneous polysaccharides found in the extracellular matrix (ECM) [45]. There are 
several forms of GAGs depending on their structure and degree of sulfates. The major GAGs that 
are found to influence AD are: Heparan sulfate (HS), Heparin (Hep), Dermatan sulfate (DS), 
Chondroitin sulfate (CS) and Hyaluronan (HA) [46, 47]. Some functions of GAGs/PGs are 
maintaining homeostasis, balance growth factor activities, balance signal transduction, and help in 
cell-to-cell interactions [45, 48-50]. It was also proven that AD can be influenced by GAGs [51] 
by affecting tau protein aggregation [52] and Aβ peptide aggregation [53]. Sulfated GAGs share 
the same location of Aβ plaques, so it was proven that GAGs bind to Aβ to induce fibrilization 
[53-57]. Additionally, GAGs induce NFTs by increasing phosphorylation of tau 
(hyperphosphorylation) depending on the degree of sulfation [52, 53, 58]. It has been reported that 
tau assemble into filaments in the presence HS [59]; also, it was proved that tau changes are 
induced in the presence of Hep [60, 61]. 
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2.3.2 Extracellular enzymes and AD  
Aβ aggregation has been proven to be stabilized by several extracellular enzymes, including 
transglutaminase (TG) and lysyl oxidase (LOX) [62-64].  One of the most studied TG member of 
the calcium-activated enzymes is the tissue transglutaminase (tTG) that was proven to be 
associated with AD [65]. It was previously shown that tTG enzymes help neurofilaments proteins 
like Aβ [66], APP [67, 68], and tau [69, 70] in cross-liking the ECM during diseases [71-73]. They 
are found in different areas of the brain like the cytoplasm of neurons [74], the nuclei, and the 
ECM (where Aβ aggregation occur) [75]. LOX are copper dependent amine oxidase enzymes that 
convert generated enzyme aldehyde residues by catalyzing lysine side chains (amines) on the ECM 
proteins [76] mainly collagen and elastin [77, 78]. These ECM proteins especially collagen 
(heparan sulfate) are associated with Aβ aggregation and the development of senile plaques [79]. 
It was experimentally proven that LOX increased by 30% in AD patients [76].  
2.3.3 CSF proteins and AD 
AD detection is limited [80, 81]; it was suggested to study the biomarkers and proteins in the 
cerebrospinal fluid (CSF) to understand more the pathology of AD [82]. Some of these molecules 
are Transferrin (Tf) and Human Serum Albumin (HSA); it was proven that Tf and HSA inhibit Aβ 
aggregation [83-86]. Tf are iron transport proteins that are used for iron homeostasis [87]; any 
mutation or interference in iron homeostasis will lead to AD due to neurotoxicity [87, 88]. 
Additionally, HSA was shown to bind to 90-95% of Aβ in blood plasma [89] which proves that 
Aβ plaques are found in the exterior of the brain [90].  Also, it was experimentally proven that 
HSA doesn’t bind to Aβ monomers, it selectively binds to Aβ fibrils (β-structures) [84].  
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2.4. Therapeutic Approaches to treat tau and Aβ aggregation 
Several therapeutic approaches have been used to inhibit tau proteins and peptides aggregation 
[91-93]. One of the approaches used is using small molecules components that were shown to have 
anti-tau aggregation properties [94, 95]. Also, previous studies showed that cationic small 
molecules and urea inhibit tau aggregation [96-98]. Another approach proved to inhibit tau 
aggregation is using macromolecules [99-101]. Some already used macromolecules that affect tau 
aggregations are D-enantiomer peptide [101], eight amino acid peptide Davunetide  [100], and D-
amino acid inhibitor peptide [101]. One of the methods to treat AD is to inhibit the overproduction 
of Aβ to clear them from the brain. The clearance of Aβ peptides/aggregates from brain using anti- 
Aβ molecules is challenging due to the blood brain barrier (BBB). There are three previously tested 
approaches to target Aβ aggregation pathways. First approach was done using ligands that directly 
affect Aβ like PEG [102] and lipid [103] based nanoparticles. Another approach was tested using 
small molecules like curcumin, melatonin [104, 105], and Aβ vaccines [106]. Also, strategies to 
target APP or β-secretase and ϒ-secretase enzymes have been investigated [107, 108]. 
2.5. Methods 
2.5.1 Aggregates Formation 
2.5.1.1    Aβ 1-42 aggregation 
Each of the Aβ forms (aggregated, unaggregated, fibrils, plaques) has its own preparation method 
[109]. In this study, we aggregated Aβ by dissolving 0.5 mg in 250 µl HFIP. Then, the Aβ-HFIP 
solution was aliquoted into five vials (100 µg/vial) and kept in a chemical hold until HFIP 
completely evaporates. Then, the vials are stored at -20 °C until usage.  The aggregation is either 
formed in PBS buffer or DMSO/10 mM HCl depending on the application.  
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2.5.1.2   Tau peptides aggregation  
Tau peptides were first dissolved in water at 1 mM concentration, and stored at -20°C until usage.  
Tau aggregation was formed in MOPS buffer at pH 7. For the tau aggregation initiation, heparin 
is mainly used in the study.  
2.5.2   Nanoparticle preparation 
Poly (lactic-co-glycolic acid) (PLGA) is a biodegradable polymer used to develop polymeric 
nanoparticles [110]. It is widely used because of its characteristics; it is biodegradable, 
biocompatible, FDA approved, adaptable to different drug types [110]. First, the PLGA 
nanoparticle was formed by emulsion. Then the particles were surface modified with EDC/NHS 
chemistry to render protein functionalization.  In this study, we coated Tf and HSA with PLGA-
NP to inhibit Aβ 1-42 aggregation.  
2.5.3 Characterization Techniques 
 2.5.3.1 Thioflavin T (ThT) fluorescence  
ThT is a dye that fluoresce at 449 nm excitation and 482 nm emission when it binds to amyloid 
fibrils [111].  In our experiment ThtT was used to detect Aβ 1-42 fibrils under different conditions.  
2.5.3.2 Thioflavin S (ThS) fluorescence 
ThS is a benzothiazole dye that fluoresce at 440 nm/ 485 nm when bind to protein aggregation 
[112]. In our study, the ThS was used to detect tau aggregation in the presence and absence of 
GAGAs. 
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2.5.3.3 Turbidity 
Turbidity is the effect of the incident beam by light scattering which can be measured directly 
(transmission) by using spectrophotometer/plate reader and indirectly static light scattering) [113]. 
Here, we measured tau peptide aggregation at 400 nm (absorption).  
2.5.3.4 Dynamic Light Scattering (DLS) 
DLS instrument is used to predict the size of the samples. Dynamic light scattering detects the 
particle size in the nanometer range, by utilizing Brownian motion principles. We used it to predict 
the size of abeta, and tau aggregation with and without biomolecules, drugs, as well as to predict 
the size of nanoparticles. 
2.5.3.5 Confocal Microscopy 
Confocal microscopy uses special optical components to form high resolution and contrast images. 
We use it to image cells after immunofluorescence staining (zo-1 staining for Aβ 1-42 with TG, 
LOX, and B/LP), and for cellular uptake of nanoparticles characterization.  
 2.5.3.6 Atomic Force Microscopy (AFM) 
AFM is a scanning force microscope that takes very-high-resolution images in an order of 
nanometer. In our study, we used AFM to image the topography of our samples tau proteins with 
and without GAGs, and Aβ 1-42 with the extracellular enzymes and the CSF proteins, by spotting 
them on a mica and imaging them in taping mode using a Hitachi AFM in the lab. 
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2.5.3.7 Transmission Electron Microscopy (TEM) 
TEM is an electron microscopy technique that forms an image of the samples by transmitting a 
beam of electron through it. The samples were spotted on a holy carbon copper grid, and then 
stained with 2% phosphotungstic acid.  
2.5.3.8 Cell Assays 
2.5.3.8.1 Cell viability 
Cell viability assay was performed using XTT assay to measure cell viability and metabolism. 
XTT measurements was used in all our studies is determined by, the formation of formazan dye 
by measuring the absorbance at 470 nm using a spectrophotometer, and then calculating the 
percentage of viability based on the difference in absorbance between control cells to that of cells 
treated with aggregates and drugs.  
2.5.3.8.2 Oxidative Stress 
The DCFH-DA assay is used to measure the oxidative stress associated with an increased 
production of reactive oxygen species. Severe oxidative stress can cause cellular death. 
Quantifying oxidative stress by 2,7-dichlorodihydrofluorescein (DCFH) based fluorescent probes 
has been widely reported [114, 115].  We studied oxidative stress of Aβ 1-42 peptides in presence 
of extracellular enzymes with and without small molecule drugs, at 485/535 nm 
excitation/emission. 
2.5.3.8.4 Immunofluorescence 
Immunofluorescence is used to detect the cellular markers due to changes and influences of the 
samples on the cells by utilizing antibody-antigen binding. The cells are stained with the cellular 
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target of interest with both primary and secondary antibodies with fluorescent dyes, and then 
imaged using confocal microscope. 
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Chapter 3: Role of Glycosaminoglycans in Tau Peptides Aggregation 
3.1 Introduction 
Tau protein aggregation and subsequent neurofibrillary tangle formation are hallmark of 
Alzheimer’s disease [1, 2]. Tau protein consists of 441 amino acids with microtubule binding 
region that contains four repeat peptide units [3, 4]. They are composed of hexapeptide domains 
VQIVYK, and VQIINK, and are believed to be the major drivers of tau pathological assembly [5-
9], and are widely used as a model to study tau aggregation in vitro.  
Several factors are known to influence the tau aggregation [5, 10-12]. Among them, polyanions, 
glycosaminoglycans (GAGs) and their sulfated forms, and RNA have shown to induce 
Alzheimer’s like changes in tau protein and believed to play a major role in tau aggregation [13, 
14]. Further, sulfated glycosaminoglycans have shown to promote tau aggregation and have been 
found to be present in Alzheimer’s disease affected brain [13, 15]. Previously, it has been shown 
that GAGs influence the aggregation of amyloid beta peptide (Aβ42) aggregation in vitro [16]. Tau 
protein also has been shown to assemble into filaments like morphology in the presence of sulfated 
heparin [17], and heparin induced conformational changes in tau protein have been observed [18, 
19]. In addition, tau peptide fragments aggregation in the presence of heparin has been investigated 
before [20]. But, the role of other glycosaminoglycan molecules on tau hexapeptides, and their 
extracellular mimetic conditions haven’t been explored in detail.  
 25 
 
Here in this thesis chapter we study the effect of GAG molecules (in solution and on surface) 
heparin (Hep), heparin sulfate (HepS), dermatan sulfate (DS), chondroitin sulfate (CS), and 
hyaluronan (HA) on the aggregation of tau peptides. The peptides used are, hexapeptide domain 
306 VQIVYK311 (Tau V) segment from the microtubule binding region of tau protein, and the tau 
mutant peptide fragment GKVQIINKLDL (Tau N), widely found in taupathy. The aggregation of 
the peptides was studied utilizing the biochemical, biophysical, and cell toxicity assays. The thesis 
study revealed that the heparin, chondroitin sulfate, and dermatan sulfate in solution, significantly 
promote tau peptides aggregation and fibril formation, while surface coated GAGs did not promote 
significant aggregation.  
3.2 Materials and Methods 
3.2.1 Materials 
Tau peptides were custom synthesized from Genscript. Low molecular weight heparin, heparin 
sulfate (GAG-HS01), and dermatan sulfate (GAG-DS01) were purchased from Galen Laboratory 
Supplies. Chondroitin sulfate (C4384), hylaluronic acid (53747), and all other chemicals, and 
reagents were purchased from Sigma Aldrich. ELISA 96 well Clear Amino Surface Plate was 
purchased from Galen laboratory supplies. 
3.2.2 ThS measurements 
First stock solutions of tau peptides (1 mM) and GAGs (1 mM) were prepared by dissolving in 
deionized water. ThS was freshly prepared at a concentration of 0.5 mg/ml in 20 mM MOPS 
buffer, pH 7.  For the ThS measurement, 10 μl of peptide was dissolved in 2.5 μl GAG stock 
solution, 10 μl ThS, and MOPS buffer to make the final 100 μl working solution. A M3 spectramax 
spectrophotometer was used to measure the ThS fluorescence at 440/490 nm, excitation and 
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emission. Aggregation kinetic measurements were performed every two minutes for 30 minutes. 
Three independent experiments were carried out and the average readings were obtained.  
3.2.3 DLS 
A Malvern zetasizer instrument in the lab was used to measure the size of the aggregation of the 
peptides with GAGs. Samples were prepared under similar conditions without the ThS, and the 
size measurements were performed. Three independent size measurement experiments were 
performed for each GAGs condition.   
3.2.4 Turbidity 
The peptides aggregation was measured by the turbidity of the samples at 400 nm. Samples were prepared 
under similar conditions without the ThS, and the turbidity measurements were performed using a 
spectramax M3 spectrophotometer in the lab. Three independent size measurement experiments were 
performed for each GAGs condition.  
3.2.5 TEM 
TEM images were obtained using the JEOL JSM 1400 TEM at UM-Ann arbor electron microscope 
facility.  The peptides were aggregated with GAGs for 1 hour, spotted on holy carbon copper grids, 
and then stained with 1% uranyl formate.  
3.2.6 Cell toxicity assay 
The toxicity of tau peptides aggregates with GAGs on human neuroblastoma SH-SY5Y cells was 
studied by the XTT assay. Cells were obtained from American Type Culture Collection (ATCC), 
and cultured according to the protocol. For the study, 2x 104 cells/well, were cultured in 96 well 
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plates overnight. Peptides (32 μM) with or without GAGs of concentrations (8 μM) were 
aggregated for 24 hours, and subsequently incubated for 48 hours.  
3.2.7 GAGs surface coating and aggregation assays 
To study the influence of surface coated GAGs on peptide aggregation, first GAGS were coated 
on GAGs binding plates. For GAGs binding, 100 µl solution of 0.01 M PBS containing 25 µM of 
GAGs (Hep, CS, DS, HepS, and HA) were added to a GAGs binding plate and incubated at room 
temperature according to manufacturer’s protocol. After 24 hours, the PBS/GAGs solution was 
aspirated and the wells were washed three times with PBS buffer. For aggregation studies on GAGs 
coated plates, 15 µl of 1 mM Tau N, 15 µl ThS (0.5mg/ml), and 120 µl MOPS (20 mM) solution 
was added into each well. The turbidity of the peptide aggregates was measured at 400 nm 
wavelength after 30 min incubation. AFM was to characterize the morphology.  
3.2.8 AFM 
Hitachi AFM 5100N was used to obtain the AFM images for tau peptides samples with GAGs. 
For preparation, 2 µl of the aggregated sample solutions were spotted on freshly cleaved mica, and 
kept to dry before imaging. AFM tips (Applied Nanostructures Inc.) with an average resonance 
frequency of 300 kHz, was used to image samples using tapping mode. The length and the width 
of the cantilever are 125 µm and 30 µm respectively, and the average force constant is 37 N/m. 
3.2.9 Statistical Analysis 
Each experiment was conducted three or more times, and they are presented as mean ± standard 
error of the mean (SEM). P-values were determined from the results of at least 3-independent 
experiments. Statistical significance was computed using analysis of variance (ANOVA), followed 
by Tukey’s HSD post-hoc analysis test. **p< 0.01, *p< 0.05 are considered as significance.   
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3.3 Results 
In this chapter we studied the influence of GAGS on tau peptides aggregation, and cellular toxicity. 
For the GAGS induced aggregation study, two different peptides to GAGs molar ratios 4:1 or 20:1 
were used. First, we used thioflavin to study the aggregation. Thioflavin S measurements show 
that the GAGs influence both Tau V, and Tau N peptides aggregation in vitro. Aggregation of the 
peptides was enhanced in the presence of chondroitin sulfate, heparin, and dermatan sulfate (Figure 
3.1 A, B). Sulfated heparin and hyaluronan on the other hand exhibited minimal aggregation effect. 
At both 4:1, and 20:1 molar ratios, chondroitin sulfate seems to influence the aggregation of Tau 
V peptide (Figure 3.1A, Figure 3.2A). Tau N aggregation is enhanced in the presence of 
chondroitin sulfate at lower molar ratios (Figure 3.2B), while at higher GAGs content, heparin 
seems to have more influence on the Tau N aggregation (Figure 3.1B). Also, it is important to note 
that, compared to heparin, the sulfated form of heparin did not exhibit significant aggregation.  
 
 
 
 
 
Figure 3.1. A). Tau V peptide (100 μM) aggregation kinetics was studied with GAGs (25 μM). B). Tau N 
peptide (100 μM) aggregation kinetics was studied with GAGs (25 μM). ThS fluorescence, show the 
aggregation is influenced by the presence of glycosaminoglycan used.   
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Figure 3.2. A). Tau V peptide (100 μM) aggregation kinetics was studied with and without GAGs (5 μM). 
B).  Tau N peptide (100 μM) aggregation kinetics was studied with and without GAGs (5 μM).  
 
DLS, and turbidity measurements were then used to measure the size distribution, and turbidity of 
the peptide aggregates, with and without GAGs. As can be seen from Figure 3.3(i), chondroitin 
sulfate, heparin, and dermatan sulfate treated Tau N peptides, exhibited larger sizes, indicating the 
presence of aggregation or fibrillar structures. As for the Tau V peptide aggregation size, 
significant increase in all the GAGs treated peptides was observed compared to Tau V peptide 
alone (Figure 3.3 (ii)). 
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Figure 3.3 A. (i). Dynamic light scattering measurements of the Tau N peptide (100 μM) aggregates with 
GAGs (25 μM). (ii) Tau V peptide (100 μM) aggregation with and without GAGs (25 μM), assessed by 
turbidity measurements.  
 
As Tau N showed significant aggregation in the presence of GAGs revealed by ThS measurements, 
next we tested the morphology of the Tau N aggregates by TEM (Figure 3.4). Images reveal, that 
the Tau N peptides treated with heparin, and chondroitin sulfate exhibited higher amount of fibril 
like structures, in agreement with the ThS measurements. Dermatan sulfate treated peptides 
exhibited aggregates like morphology. Also in agreement with the ThS measurements, the TEM 
images of heparin sulfate, and hyaluronan treated samples showed less aggregated structures 
compared to other GAGs treated samples.  
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Figure 3.4. A). TEM images of Tau N peptide aggregation in the presence of GAGs. Scale bar 1 μm.  
 
Next, we tested whether aggregation tendencies were observed under extracellular mimetic 
conditions. As stated before, since Tau N exhibited significant aggregation in solution in the 
presence of GAGs as revealed by ths (Figure 3.1), we tested their aggregation tendency due to 
surface coated GAGs. For this, GAGs were coated on special GAGs binding plates, and then Tau 
N peptides solutions were subsequently incubated on the surface. As can be seen from AFM 
images in Figure 3.5, all the GAGs exposed peptides showed some aggregation tendency. 
However, the amount of aggregates seems to be less, compared to the aggregation formed due to 
the presence of GAGs in the solution form. To further confirm this, we did turbidity measurements. 
As can be seen from Figure 3.6, there is no significant difference among different GAGS treatment 
compared to untreated GAGs. Although chondroitin sulfate showed more aggregation/fibril 
formation revealed from both AFM and turbidity, it was not statistically significant. The data 
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suggests, that the intracellular GAGs may have major role in tau aggregation compared to 
extracellular GAGs.  
Figure 3.5. AFM images of Tau N peptide aggregation in the presence of GAGs coated surfaces. Scale bar 
500 nm.  
 
 
 
 
 
 
 
 
 
Figure 3.6. Tau N peptide aggregation with and without GAGs coated surfaces, assessed by turbidity 
measurements. 
 
To assess the toxicity effects of GAGs on tau peptide aggregation, we performed cellular toxicity 
studies of Tau N and Tau V aggregated samples in the presence of GAGs. For the study, we used 
SH-SY5Y human neuroblastoma cells, that is widely used as a model cell line in 
neurodegenerative disease studies to assess the toxicity effects [21].  Cells were cultured in 96 well 
plates and incubated with Tau peptides and GAGs for 48 hours and XTT assay was performed to 
assess the cell viability. As can be seen from the Figure 3.7, all the samples treated with GAGs 
exhibited toxicity effects. While dermatan sulfate treated samples show a slight increase in 
Tau N Tau N  
+ Hep 
Tau N  
+ CS 
Tau N  
+ DS 
Tau N  
+ HepS 
Tau N  
+ HA 
Turbidity @ 400 nm (p.d.u.) 
0.25 
 
0.2 
 
0.15 
 
0.1 
 
0.05 
 
0 
Tau N Tau N + Hep Tau N + CS Tau N + DS Tau N + HS Tau N + HA 
 33 
 
toxicity, statistically it is not significantly different from other GAGs treated samples indicating 
the importance of all the GAGs in peptide aggregation mediated toxicity. The enhanced toxicity 
in the presence of dermatan sulfate may be due to its influence in the formation of aggregates like 
morphology compared to fibrillar structures as observed from the TEM images. Finally, we have 
tested the toxicity effect of GAGs alone. Cell viability assay reveal, none of the GAGs exhibited 
toxicity to SH-SY5Y cells (Figure 3.8). 
 
 
 
 
Figure 3.7. Toxicity effect of Tau peptides aggregates with GAGs on SH-SY5Y cells. A) Tau N with GAGs 
B) Tau V with GAGs. Peptides in the presence of GAGs exhibited significant toxicity, *p< 0.05.  
 
 
 
 
 
 
 
 
Figure 3.8. Effect of GAGs on SH-SY5Y cells viability. The toxicity data show no significant toxicity of 
GAGs at the tested concentrations (8 µM) relevant to the study.   
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3.4 Discussion 
Glycosaminoglycans have shown to play a key role in Alzheimer’s disease. A recent study 
suggest that N-glycans may play an important role in Alzheimer’s disease [22]. In another study, 
it is stated that GAGs have a scaffolding role on amyloidogenic proteins [23]. Further, it has been 
reported that glycosaminoglycan heparin, which is anionic in nature, believed to play a key role 
in the tau aggregation by interacting with the microtubule binding region [13, 18]. Here we show 
that GAGS, both in solution and on surface, have the capability to influence the tau peptides 
aggregation, fibrillization and toxicity in vitro. As far as GAGs are concerned, chondroitin 
sulfate, dermatan sulfate, and heparin seem to influence the peptide aggregation more compared 
to other GAGs. Although it has been reported that the sulfated form of heparin is found in the 
amyloid plaques, it did not promote significant aggregation of tau peptides under in vitro 
conditions. Hyaluronan showed the least aggregation promoting effects among the GAGs 
studied. Further, the GAGs in solution seems to have more influence on the aggregation 
compared to the surface coated GAGs. 
3.5 Conclusion 
From this thesis chapter study, we show that GAGs influence the tau peptides aggregation under 
in vitro conditions. The kind of glycosaminoglycan, and the sulfate modifications, and the physical 
representation also seems to influence the aggregation mechanism. This study could open further 
opportunities for the investigation of polyanions associated tau aggregation mechanisms and 
therapeutic interventions.  
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Chapter 4: Tau peptides and tau mutant protein aggregation inhibition by cationic 
polyethyleneimine and polyarginine 
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4.1 Abstract 
Tau protein plays a major role in Alzheimer’s disease. The tau protein loses its functionality by 
self-aggregation due to the two six-amino acid sequences VQIVYK, and VQIINK of the protein. 
Hence it’s imperative to find therapeutics that could inhibit the self-aggregation of this tau peptide 
fragments. Here we study the inhibitory potential of a cationic polymer polyethyleneimine (PEI), 
and a cationic polypeptide arginine (Arg) on the aggregation of VQIVYK, and GKVQIINKLDL 
peptides, and tau mutant protein (P301L), found frequently in taupathy. Various characterization 
methods are employed including thioflavin T, transmission electron microscopy (TEM), and 
dynamic light scattering (DLS) to study the aggregation/inhibition process in vitro. Results show, 
PEI and Arg significantly inhibit tau peptides and protein aggregation. The study could be applied 
to understand tau protein aggregation mechanism in the presence of cationic polymers. 
Key words: Aggregation, tau peptide, polyethyleneimine, polyarginine, inhibition, cation. 
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4.2 Introduction 
Tau protein plays an important role in the regulation of microtubules in the brain. During 
Alzheimer’s and related pathological conditions, tau has been shown to dissociate from the 
microtubule, self-aggregates, and form neurofibrillary tangles [1, 2]. Cell to cell transmission of 
the aggregates and fibrillar structures results in neuronal cell death and subsequent progression of 
the Alzheimer’s [3, 4]. The hexapeptide repeats VQIVYK, and VQIINK found in the carboxyl 
region of the tau protein, believe to be the drivers in the formation of inter-tau beta sheets, and 
subsequent aggregation and fibril structures [2, 5, 6]. The hexapeptide repeats are well 
characterized, and have shown to form beta-sheets, and subsequent fibrillar assembly with cross 
beta sheet structure, in vitro [6, 7]. They are widely used as a model to study tau aggregation, and 
for the investigation of therapeutic interventions of this pathologic aggregation [4, 6, 8].  
Several therapeutic modalities for the inhibition of tau peptide/protein aggregation have been 
reported [9, 10]. Among the approaches, the use of small molecule compounds has recently gained 
a lot of interest. Several small molecules have shown to exhibit anti-tau aggregation properties 
against tau peptides and protein [11, 12]. However, there have been only few studies reported on 
the effect of macromolecules on tau aggregation mechanism and in tau pathology [13-15]. Recent 
study by Dammers and others show the modulation of tau aggregation mechanism by D-
enantiomer peptides [13]. Other macromolecules that have been shown to have effect on tau 
pathology are, an eight amino acid peptide Davunetide [14], and a D-aminoacid inhibitor peptide 
[15]. By studying the macromolecules-tau interaction, further insights on tau aggregation 
mechanism and inhibition could be unraveled, and could aid in the development of tau aggregation 
inhibitory molecules, and drug delivery strategies. Previous studies have shown that cationic small 
molecules, and cationic osmolyte urea have inhibitory potential on tau aggregation [8, 16, 17]. 
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However, effect of cationic polymers on tau peptide aggregation inhibition hasn’t been explored 
in detail yet. We are particularly interested in studying the cationic polyethyleneimine and 
polyarginine polymers on their effect on tau aggregation.  
Here in this paper we investigated the inhibitory potential of the cationic polymers PEI and PR on 
the aggregation of tau hexapeptide domain 306 VQIVYK311 (Tau V) segment from the microtubule 
binding region of tau protein, and the peptide fragment GKVQIINKLDL (Tau N), which is widely 
found in taupathy. The peptides are well characterized and have been used as models to study the 
tau aggregation [6, 8]. In addition, to have a physiologically closer mimic, we also investigate the 
aggregation inhibition of a mutant tau protein (P301L), found in adult brains affected by taupathy 
[18, 19]. The aggregation with and without the cationic polymer, and polypeptide/protein were 
studied utilizing the standard peptide aggregation characterization methods thioflavin S, TEM, and 
dynamic light scattering (DLS). The results show that the cationic PEI and Arg, exhibited 
significant inhibitory effect on the tau peptides and protein aggregation. The study demonstrates 
for the first time that cationic polymers could inhibit tau peptide and protein aggregation, and could 
be used as model compounds to study the tau aggregation mechanism in vitro. 
4.3 Materials and Methods 
4.3.1 Materials 
Tau peptides, and corresponding mutant peptides were custom synthesized from Genscript. Tau 
mutant protein, P301L was obtained from rPeptide. Low molecular weight heparin was purchased 
from Galen laboratory supplies. All other chemicals, and reagents were purchased from Sigma 
Aldrich. The polyethyleneimine-branched (Mw 25,000, cat no: 408727), and poly-l-arginine 
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hydrochloride (Mw 5,000-15,000, cat no: P4663) were obtained from Sigma Aldrich, and was 
used as obtained. 
4.3.2 Thioflavin S (ThS) fluorescence measurement 
Tau peptides stocks of 1 mM were prepared by dissolving in deionized water. ThS of 0.5 mg/ml 
was freshly prepared with 20 mM MOPS buffer, pH 7. 1 mM Heparin stock solutions were 
prepared by dissolving in deionized water. For the ThS assay, 10 μl of peptide was dissolved in 
2.5 μl heparin, 10 μl ThS, and MOPS buffer with or without the cationic inhibitors to make the 
final 100 μl working solution. ThS fluorescence was measured at 440/490 nm excitation and 
emission using a spectrophotometer in the lab. Kinetic measurements were performed with 2 
minutes interval for 30 min. The experiments were repeated for three independent experiments. 
4.3.3 DLS 
DLS measurements were performed using a Malvern zetasizer instrument in the lab. Samples were 
prepared under similar conditions without the ThS, and diluted 10 times, and the size 
measurements were performed. The experiments were repeated for three independent experiments.  
4.3.4 TEM 
For TEM imaging, the peptides, after 2 hours of aggregation were spotted on holy carbon copper 
grids, and then stained with 1% uranyl formate. The samples were then be imaged using the JEOL 
JSM 1400 TEM at UM-Ann arbor electron microscope facility.   
4.3.5. Cell toxicity assay 
The toxicity of PEI and Arg on normal human neuroblastoma SH-SY5Y cells was studied by the 
XTT assay. Cells were obtained from the American Type Culture Collection (ATCC), and were 
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cultured according to the manufacturers protocol. We have also tested the toxicity effect of Tau N 
on these cells. For the study, 2x104 cells/well, were cultured in 96 well plates over night. For PEI 
and Arg toxicity, PEI concentrations of 50-200 nM, and Arg concentrations of 1- 4 μM were 
incubated for 48 hours.  For Tau N toxicity study, Tau N concentrations of 10, 20, and 40 μM were 
tested with and without PEI and Arg. XTT assay was performed at 470 nm, and the viability was 
determined according to manufacturer’s protocol. 
4.3.6 Statistical Analysis 
Data were collected from three or more replicates for each experiment, and they are presented as 
mean ± standard error of the mean (SEM). P-values were determined from the results of at least 3-
independent experiments for statistical significance unpaired T-test was used.  
4.4 Results and Discussion 
The approach used for the study is depicted in Figure 4.1. The goal of the study is to test the 
potential of cationic polymer PEI and cationic peptide Arg on the inhibition of tau peptide/protein 
aggregation, and subsequent fibril formation. First, we performed thioflavin S measurements to 
probe the aggregation kinetics of the tau peptides with and without PEI and Arg. The thioflavin S 
measurements show that the cationic polymers successfully inhibit both Tau V, and Tau N peptides 
aggregation in vitro. The kinetic study show, faster aggregation for peptides without any inhibitors. 
PEI with hundred times lower molar concentrations was able to inhibit both peptides aggregation, 
while Arg with about ten times lower molar concentrations was able to inhibit the peptides Tau N 
(Figure 4.2), and Tau V (Figure 4.3) aggregation. To confirm, that the aggregation of Tau N, and 
Tau V is sequence specific, we did scrambled peptides VKYVIQ, and GKIVQNIVLKKLD 
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aggregation. As can be seen from Figure 4.4, the scrambled peptides did not show significant 
aggregation, indicating the importance of hexapeptides domain in tau aggregation. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Schematic of the approach used. Proposed tau peptides aggregation inhibition by cationic 
polymer polyethyleneimine and cationic polypeptide polyarginine 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Tau N peptide (100 uM) aggregation kinetics was studied with and without PEI and Arg at 
concentrations depicted in the figure. Thioflavin S fluorescence show significant inhibitory effect of both 
PEI (A), and Arg (B) on Tau N aggregation. 
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Figure 4.3. Tau V peptide (100 uM) aggregation kinetics was studied with and without PEI and Arg at 
concentrations as depicted in the figure. Thioflavin S fluorescence show significant inhibitory effect of both 
PEI  (A), and Arg (B) on Tau V aggregation 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Scrambled peptides aggregation kinetics was studied with Thioflavin S binding assay. 
Thioflavin S fluorescence, indicate the scrambled peptides did not exhibit significant peptide aggregation.  
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We then tested the morphology of the Tau N and Tau V aggregates with and without PEI and Arg 
using TEM. Images reveal, that the tau peptide Tau N fibers formed more fibrils compared to the 
Tau V aggregates, corroborating the ThS data. PEI, and Arg in few micromolar concentrations 
were able to effectively inhibit the aggregation of 100 μM peptides as seen in Figure 4.5, and is in 
agreement with the ThS data. Further, as a complementary technique, we performed dynamic light 
scattering measurements to study the size of the peptides aggregation with and without PEI and 
Arg. The size measurements for GKVQIINKLDL (Tau N) aggregation show, that the aggregation 
size is reduced in the presence of polyethyleneimine or polyarginine, in corroboration with the 
ThS and TEM measurements (Figure 4.6). 
 
 
 
 
 
 
 
 
Figure 4.5. TEM images show the tau peptides aggregation inhibition in the presence of PEI and Arg. (A) 
Tau N, with and without PEI or Arg, (B) Tau V, with and without PEI or Arg. Scale bar 1 μm. 
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Figure 4.6. Dynamic light scattering measurements of the Tau N peptide aggregation with and without PEI 
(A) or Arg (B), indicating the reduction in aggregation size in the presence of PEI or Arg. 
 
We then studied the inhibitory effect of the cationic polymers on tau mutant protein aggregation. 
The aggregation inhibition of a mutant tau protein (P301L), found in adult brains affected by 
taupathy was studied. To test the effect of aggregation inhibition, we performed aggregation 
kinetics of tau mutant protein aggregation with and without PEI and Arg similar to the peptide 
aggregation experiments described earlier. As can be seen from ThS measurements (Figure 4.7A), 
DLS (Figure 4.7B), and TEM images (Figure 4.7C), the cationic polymers are able to inhibit the 
protein aggregation.  
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Figure 4.7. Tau mutant protein (100 nM) aggregation inhibition studies show that PEI and Arg were able 
to inhibit protein aggregation A) Thioflavin S, B) Dynamic light scattering, and C) TEM images. Scale bar 
1 μm.  
 
Finally, to assess whether the cationic peptides have toxicity effects in normal cells, we performed 
cellular toxicity studies on normal cells in the presence of PEI and Arg with varying 
concentrations. For the study, we used SH-SY5Y human neuroblastoma cells, which is also used 
as a model cell line in neurodegenerative disease studies [20], and hence would be a suitable for 
our study.  Cells were cultured in 96 well plates and incubated with PEI and Arg for 48 hours and 
XTT assay was performed to assess the cell viability. As can be seen from the Figure 4.8, no 
significant toxicity was observed from PEI or Arg up to a few micro molar concentrations. We 
have also tested the toxicity effects of Tau N on SH-SY5Y cells (Figure 4.9). Tau N exhibited 
toxicity around 40 μM of peptide concentration, while the lower concentrations showed no toxicity 
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concentrations (Figure 4.9B, C).  Hence, the cationic polymers, could have therapeutic potential 
against tau aggregation.  
 
 
 
 
 
 
 
Figure 4.8. XTT assay show no significant decrease on the cell viability of SH-SY5Y cells in the presence 
of (A) PEI or (B) Arg at few micromolar concentrations. 
 
 
 
 
 
 
Figure 4.9. Tau N toxicity effect on SH-SY5Y cells. A) Tau N alone B) Tau N with 200 nM PEI C) Tau 
N with 2 μM Arg. * p < 0.05. Data are expressed as mean ± SEM. 
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Here we show that cationic polymers have the capability to inhibit tau mutant fibrillization in vitro. 
It is widely known that microtubules and polyanions contribute to the neurofibrillary tangle 
formation [21, 22], and glycosaminoglycans, which are anionic in nature, believed to play a key 
role in the tau aggregation [23, 24]. Hence, by interacting with the glycosaminoglycan heparin that 
is used in the study, the cationic PEI and Arg could have prevented the tau peptides and protein 
aggregation. Previously, it has been reported that several cationic small molecule compounds such 
as, cyanine, phenothiazine, and arylmethine in micromolar concentrations, exhibited inhibitory 
effects by interacting with the nucleation process mediated by the tau peptides [16]. Another recent 
study report the inhibitory effect of urea, a cationic osmolyte on tau fibrillization [8]. These studies 
further indicate the influence of cationic molecules on tau aggregation inhibition, and the current 
study would provide new insights and future investigation on the influence of cationic 
macromolecules on tau aggregation. 
4.5 Conclusion 
The cationic polymers PEI and Arg, exhibited inhibitory effects on tau peptides, and protein 
aggregation in vitro, and could aid in understanding the mechanism of tau aggregation inhibitory 
process. Further, they could to be used as drug carriers for treating tau aggregation. PEI and Arg 
have shown potential in gene delivery [25-28], and hence could be used in Alzheimer’s gene 
therapy. Arg is also known for its cell penetrating capabilities [29, 30], and could be used as a drug 
depot for effective intracellular delivery of therapies for tau aggregation, which is mainly observed 
inside the cells [4, 19]. From this proof of concept study, we show that the cationic polymeric 
compounds may serve as potential inhibitors for tau peptide aggregation, and could be applied to 
study the mechanism of tau protein aggregation.  
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Chapter 5: Role of extracellular enzymes in Alzheimer’s peptides aggregation 
 
5.1 Introduction 
Alzheimer’s disease is characterized by senile plaques and neurofibrillary tangles in the brain 
tissue [1-4]. Several extracellular matrix factors play a role in promoting and stabilizing abeta and 
tau aggregation [5-8]. Among them extracellular enzymes are one of the key constituents found 
co-localized with abeta and tau aggregates [6, 8]. Extracellular enzymes transglutaminase (TG), 
and lysyl oxidase (LOX) are known to crosslink the extracellular matrix and modulate the ECM 
during diseases [6, 8, 9]. Recent studies report that both TG, and LOX have been observed in 
Alzheimer’s disease brain tissues [9-12]. Transglutaminase is believed to contribute to 
Alzheimer’s pathology by either directly binding to abeta and tau, or modulating the protein 
aggregation cascade and neurotoxicity by crosslinking the ECM [13, 14]. The result is the 
production of neurotoxic and protease resistant abeta and tau. Lysyl oxidase, which is known to 
play a major role in collagen crosslinking also believe to contribute to abeta pathology in a similar 
manner [9].  
Here in this chapter, we study the effect of extracellular enzymes transglutaminase and LOX 
peptide on the aggregation of Aβ (1-42) and tau peptide (VQIVYK) that are found predominantly 
in Alzheimer’s disease patients. In addition, we study the potential of natural antioxidants betaine 
and l-proline in inhibiting transglutaminase and lysyl oxidase mediated aggregation and 
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fibrillization. Proline and betaine are known to influence protein solvation, prevent aggregation 
and misfolding [15]. Further, recently it has been shown they have inhibitory potential on human 
serum albumin, and insulin aggregation/fibril formation [16, 17].  Hence, they could have 
inhibitory effect on extracellular enzyme mediated abeta and tau aggregation. The studies were 
carried out using thioflavin T (ThT), atomic force microscopy (AFM), cell toxicity assay (XTT), 
and oxidative stress assays. The results show that transglutaminase (TG), and lysyl oxidase peptide 
(LOX) promote the aggregation and fibrillization of Aβ (1-42), and oxidative stress. Further, 
betaine (B) and l-proline (LP) inhibited the effect of TG and LOX induced Aβ (1-42) fibrillization, 
and oxidative stress. However, at the tested conditions, tau peptide aggregation was not promoted 
in the presence of transglutaminase or lysyl oxidase.  
5.2 Materials and Methods 
5.2.1 Materials  
Abeta peptide (1-42), ultra-pure (1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) treated), is 
purchased from rPeptide. Tau peptides were custom synthesized from Genscript.  
Transglutaminase (TG) was purchased from either modernized pantry LLC or Ajinomoto. 
Human Lysyl oxidase peptide (LOX- (EDTSCDYGYHRRFA)) was custom synthesized from 
Genscript. L-proline (LP) and betaine (B), and all other chemicals were purchased from Sigma 
Aldrich. 
5.2.2 Stock Solutions Preparation 
1mg of Beta-Amyloid (1-42) was dissolved in 500µl HFIP. Then, the solution was aliquoted into 
ten vials (100µg/vial), and was kept in a chemical hood for complete evaporation of HFIP 
overnight. One vial of Aβ (1-42) was dissolved in 500µl HCl (10mM) and 10 µl of DMSO to get 
a final concentration of 48µM (stock). For transglutaminase (TG) 5% of solution was freshly 
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prepared by dissolving 50mg/ml in water. Betaine (B) and L-proline (LP) were dissolved in HCl 
(10mM) and DMSO to a final concentration of 10M (stock). Tau peptides stocks (1mM) were 
prepared by dissolving in water.  
5.2.3 ThT Fluorescence Measurement 
For the aggregation study, 3.2 mg/ml concentration of Tht was prepared in Tris buffer, pH 8. For 
Tht measurement, 50µl of 48µM Aβ (1-42), 1.1 µl of 5%, 2.5% or 1% TG or 1.25 ul or 2.5 ul of 
10 mM LOX, and 0.5ul of 10M B or LP were dissolved in HCl (10mM) and 2% DMSO to make 
the final working solution. The samples were kept to aggregate for 24 hours in an incubator at 
37°C. For the tau peptides aggregation, 10 μl of peptide was dissolved in 10 μl ThS, and MOPS 
buffer with or without TG or LOX to make the final 100 μl working solution. Spectramax M3 
spectrophotometer was used to measure the Tht fluorescence at 440/482 nm excitation/emission. 
Abeta aggregation end points were measured at 24, and 48 hours. Tau aggregation was measured 
at 440/490 nm, every 2 minutes interval for 30 min. Three independent experiments were done, 
and the average readings were obtained. 
5.2.4 AFM 
AFM images were obtained using Hitachi AFM5100N in the lab. Abeta peptide was aggregated 
in the presence of TG or LOX, and with and without the small molecule drugs betaine and l-
proline, similar to thioflavin t sample preparations. After 24 hours of incubation, 5µl of the 
solutions were spotted on a freshly cleaved mica and kept to dry before imaging. Tapping mode 
was used to image the samples, and AFM tips (Nanosensor, CA), with a resonance frequency of 
45-115 kHz was used. The average length and width of the cantilever is 225 and 28 micrometers, 
and the force constant of the tip is 0.5-9.5 N/m. A scan area of 1 x 1 or 5x 5 um is imaged for at 
least 2 different samples of each condition.  
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5.2.5 DCFH-DA assay 
The effect of oxidative stress of abeta peptide, in the presence of extracellular enzymes, and small 
molecule drugs on human Brain Endothelial Cells (hBMVEC) was studied by DCFH-DA assay. 
Quantifying oxidative stress by 2,7-dichlorodihydrofluorescein (DCFH) based fluorescent probes 
has been widely reported [18, 19]. For the study, hBMVEC cells were used. The cells were kindly 
provided by Dr. Kalyan Kondapalli at UM-Dearborn, and were cultured in medium containing M-
199, supplemented with 10% FBS, and 5% PenStrep according to the standard protocol. For this 
experiment, 2x104 cells/well were cultured in a 96 well plate for 24 hours overnight. Cells were 
then treated with final concentrations of abeta peptide (2µM), TG (0.005%) or LOX (0.0005 %), 
and the small molecule osmolyte drugs (5mM), and subsequently were incubated for 48 hours. 
DCFH-DA assay fluorescence was performed at 485/535 nm, excitation and emission. Three 
independent DCFH-DA experiments were performed, and the average readings were obtained. 
5.2.6 Cell toxicity assay 
The toxicity of Aβ (1-42) fibrils in the presence of transglutaminase and drugs on human brain 
microvascular endothelial cells (hBMVEC) was studied by XTT assay. Cells were cultured at 
2x104 cells/well in a 96 well plate overnight. Aβ (1-42) was dissolved in 200 ul PBS and 0.6 ul 
ammonium hydroxide (20-30%) to a final concentration of around 19.2 µM. For transglutaminase 
(TG) 10% solution was freshly prepared by dissolving 100 mg/mL in water, and Betaine (B) and 
L-proline (LP) were dissolved in water to get a final concentration of 10M. Cells were then treated 
with final concentrations of, abeta peptide (2 µM), TG (0.005%), and with and without small 
molecule drugs (5 mM), and subsequently were incubated for 48 hours. The XTT assay was 
analyzed by the formazan production at 470 nm, using a M3 spectrophotometer according to the 
manufacturer’s protocol. 
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5.2.7 Immunofluorescence 
hBMVEC cells were cultured in 8 well chambers at 2 x 104 cell density, and abeta with and without 
extracellular enzymes, and osmolytes were added to the wells, similar to the XTT experimental 
conditions. Cells were then incubated for 48 hours. Immunostaining of ZO-1 (purchased from cell 
signaling technology) was performed following standard staining protocol. Immunofluorescence 
images of tight junctions were obtained using a Nikon A-1 spectral confocal microscope at the 
UM-Ann Arbor microscopy image analysis laboratory (MIL), and images were obtained for 2 
different samples of each condition.  
5.2.8 Statistical Analysis 
In this study, each experiment was conducted three or more times, and they are presented as mean 
± standard error of the mean (SEM). P-values were determined from the results of at least 3-
independent experiments. Statistical significance was computed using analysis of variance 
(ANOVA), and Tukey’s HSD post-hoc analysis test was performed. **p< 0.01, and *p<0.05 were 
considered as significance.   
5.3 Results and Discussion 
First in this chapter study, we tested whether TG and LOX promote aggregation of the peptides. 
The aggregation studies were analyzed by thioflavin T, thioflavin S, and AFM measurements. The 
thioflavin T measurements of abeta aggregation show that the both TG and LOX significantly 
promote abeta aggregation (Figure 5.1 A, B).  On the other hand, no significant aggregation was 
observed with tau peptides treated with TG or LOX (Figure 5.2 A, B). Since abeta exhibited 
significance aggregation in the presence of TG and LOX, we focused our rest of the study on abeta. 
We then tested the effect of l-proline and betaine on abeta aggregation in the presence of TG or 
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LOX.  The thiolfavin-T measurements reveal, inhibition of TG and LOX mediated aggregation in 
the presence of B and LP (Figure 5.3A, B). AFM images corroborate the findings. From Figure 
5.4, it can be seen that TG and LOX promote fibrillar morphology of abeta. When aggregated in 
the presence of l-proline less fibril or aggregation was observed (Figure 5.4).  
 
 
 
 
 
 
 
 
Figure 5.1. Thioflavin-T fluorescence measurements of abeta peptide aggregation. A). Abeta peptide (45 
μM) aggregation in the presence of 0.1%, 0.05%, and 0.01% transglutaminase B). Abeta peptide (45 μM) 
aggregation in the presence of 0.01%, 0.005%, and 0.0025% of lysyl oxidase. ThT fluorescence 
measurements indicate that the abeta aggregation is promoted in the presence of extracellular enzymes.  
Data with significance compared to abeta is represented as **p<0.01. 
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Figure 5.2. Thioflavin-S fluorescence measurements of tau peptide aggregation kinetics. A). Tau peptide 
VQIVYK (100 μM) aggregation in the presence of 0.1%, 0.05%, and 0.01% transglutaminase B). Tau 
peptide (100 μM) aggregation in the presence of 0.01%, and 0.005% of lysyl oxidase. Ths fluorescence 
measurements indicate that the tau aggregation is not promoted in the presence of extracellular enzymes 
alone. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Thioflavin-T fluorescence measurements of abeta peptide aggregation. A). Abeta peptide (45 
μM) aggregation in the presence of 0.1% transglutaminase and 5 mM of osmolytes l-proline and betaine 
B). Abeta peptide (45 μM) aggregation in the presence of 0.01% of lysyl oxidase, and 5 mM of osmolytes 
l-proline or betaine. ThT fluorescence measurements indicate that the abeta aggregation is modulated by 
the presence of extracellular enzymes and osmolytes.  Data with significance is represented as 
**p<0.01. 
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Figure 5.4. Morphology of abeta peptide (45 μM) aggregation in the presence of TG, LOX, and osmolytes 
l-proline and betaine, imaged by atomic force microscopy. The images reveal abeta 
aggregation/fibrillization is promoted in the presence of TG and LOX, and inhibited in the presence of l-
proline and betaine. Scale bar 100 nm.  
 
Next oxidative stress measurements were performed to determine whether abeta, with and without 
the extracellular enzymes and small molecules exhibit oxidative stress. For the study human brain 
microvascular endothelial cells (hBMVEC) were used. First, we tested the effect of 
transglutaminase induced oxidative stress. As can be seen from Figure 5.5A, transglutaminase 
indeed promote oxidative stress of abeta aggregates. The oxidative stress effects were significantly 
inhibited in the presence of l-proline and betaine (Figure 5.5A). The oxidative stress measurements 
were then performed with lysyl oxidase treated samples. Cells treated with abeta and lysyl oxidase 
exhibited enhanced oxidative stress. When treated with the osmolytes significant inhibition in the 
oxidative stress was observed (Figure 5.5B).  
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Figure 5.5. Effect of abeta induced oxidative stress on hBMVEC with and without extracellular enzymes 
and small molecules A). Oxidative stress induced by Abeta peptide (2 μM) in the presence of 
transglutaminase, and osmolytes l-proline and betaine B). Oxidative stress induced by Abeta peptide (2 
μM) in the presence of lysyl oxidase peptide and osmolytes l-proline and betaine. Oxidative stress is 
significantly reduced in the presence of osmolytes. Data with significance is represented as **p<0.01, *p< 
0.05. 
 
To assess whether abeta and extracellular enzymes play a role in blood brain barrier damage, we 
performed immunofluorescence staining of ZO-1. The cytoplasmic accessory protein ZO-1, under 
normal conditions distribute continuously around the cell membrane [20]. However, in the 
presence of abeta, it has been shown that the tight junctions were disrupted, and broken ZO-1 links 
were observed [20]. Similarly, in this study as can be seen from Figure 5.4, when the cells were 
treated with abeta or abeta with TG or LOX, the ZO-1 staining is diffused compared to the control 
cells without any treatment. Moreover, when the cells were co-treated with osmolytes betaine or 
l-proline, significant restoration of cell junctions were observed (Figure 5.6). This finding is in 
corroboration with that of oxidative stress findings, where increased and decreased oxidative stress 
were observed in the presence of extracellular enzymes, and small molecule drugs.  
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Figure 5.6. Blood brain barrier damage induced by abeta peptide (2 μM) aggregation in the presence of 
transglutaminase and osmolytes l-proline and betaine, visualized by tight junction protein ZO-1. Tight 
junction is significantly restored in the presence of osmolytes. Scale bar 10 μm. 
 
Finally, we tested the toxicity effects of abeta with and without extracellular enzymes and small 
osmolyte molecules. For the toxicity study we used human brain microvascular endothelial cells 
(hBMVEC). Cells were treated with abeta and combination of the enzymes and drugs for 48 hours, 
and XTT assay was performed. However, as can be seen from Figure 5.7, at the tested 
concentrations, no significant toxicity was observed with all the treatment combinations of abeta, 
extracellular enzymes, and small drug molecules.   
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Figure 5.7. Assessment of toxicity effect of abeta peptide aggregates (2 μM) in the presence of 
transglutaminase (0.005%) and osmolytes (5 mM) in human brain microvascular endothelial cells. No 
significant difference in XTT absorbance is observed at the tested conditions. 
 
5.4 Conclusion 
In this chapter, we show that extracellular enzymes have the capability to influence the abeta 
peptides aggregation, fibrillization, and oxidative stress in vitro. As far as tau peptides aggregation 
is concerned, unlike glycosaminoglycans, which are known to promote tau aggregation 
significantly [21, 22], extracellular enzymes alone seem to be not enough to promote the 
aggregation. Extracellular enzymes have been shown to colocalize with amyloid plaques, and 
subsequently crosslink them and prevent them from degradation [9]. This in turn leads to excessive 
oxidative stress and neuronal death. In this study, we show, in the presence of osmolytes, the 
aggregation, and oxidative stress effects could be minimized. Hence, osmolytes could be applied 
to inhibit or prevent extracellular enzymes mediated abeta aggregation/fibrillization and oxidative 
stress, and mitigate potential long-term toxicity effects. 
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Chapter 6: Role of cerebral fluid proteins in abeta peptide aggregation 
 
6.1 Introduction 
During Alzheimer’s disease, increase in abeta concentration has been shown to be present in the 
blood and in brain [1]. The large amount of abeta is believed to contribute to the disease either by 
crossing the blood brain barrier and facilitates aggregation formation in the brain or by preventing 
abeta clearance from the brain to the circulation. One way to prevent this large amount of abeta, is 
to sequester the excess abeta in the blood, and in the brain. Cerebrospinal fluid (CSF) proteins 
transferrin and human serum albumin has been shown to inhibit abeta aggregation. The proteins 
believed to bind to the abeta oligomer, and prevent abeta monomer binding to free abeta oligomers, 
and hence subsequent aggregation and plaque formation [2]. Hence there is growing interest in 
utilizing cerebral proteins to treat Alzheimer’s. Hence a cerebral protein drug depot that can 
capture the excess abeta in the blood or in the brain could prevent unwanted abeta aggregation, 
oxidative stress, and subsequent cell toxicity leading to Alzheimer’s disease.  
Transferrin is a 79 kDa glycoprotein found in plasma, human serum, cerebrospinal fluid (CSF), 
and brain. Recent studies show that transferrin has protective role in abeta aggregation formation. 
Transferrin has been shown to bind the abeta oligomer preferentially, and prevent abeta oligomers 
nucleation and hence subsequent aggregation and plaque formation. In addition, transferrin is an 
iron transport protein that is used for iron homeostasis [3].   Abundant free ions have been also 
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known to induce toxic forms of abeta, promoting aggregation. Hence transferrin has major 
inhibitory role in preventing abeta toxicity. It was shown that any failure and malfunction in iron 
homeostasis will lead to neurotoxicity which will in turn lead to AD [3-6].  
Another CSF protein that exhibit abeta protein aggregation inhibitory effects is human serum 
albumin. When AD patients treated with plasma replacements containing abeta-free human serum 
albumin, decreased abeta accumulations in the brain and cognitive impairment was observed. 
Further, HSA promoted neuronal survival by preventing amyloid entering into brain neurons. HSA 
binds to 90-95% of Aβ in blood plasma [7, 8].  The concentration of HSA was found to be higher 
in blood plasma (640µM) [9] compared to low concentration of HSA (3 µM) in CSF [10]. This 
proves why Aβ plaques are found in the exterior space of the brain [11]. Normally, Aβ clearance 
mechanism is formed when Aβ bounds to albumin and then transported from brain into blood 
along Aβ concentration gradient [12, 13]. Also, it was shown that Aβ-albumin complexes 
decreased in blood, which showed that Aβ transport from brain to blood also decreased in AD 
patients [14].  
In this chapter we study how HSA and transferrin proteins decrease Aβ (1-42) aggregation under 
different conditions. Free proteins or proteins coated on poly (lactic-co-glycolic acid) (PLGA) 
nanoparticles to enhance their specificity in targeting Aβ, and to cross blood brain barrier (BBB) 
easily were used for the study. The aggregation studies were characterized using thioflavin T 
(ThT), atomic force microscopy (AFM), confocal microscope, and dynamic light scattering (DLS). 
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6.2 Materials and Methods 
6.2.1 Materials 
Abeta peptide (1-42), ultra-pure (1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) treated), was 
purchased from rPeptide. Transferrin (77-81 kDa), and Human Serum Albumin (66.4 kDa) 
were purchased from Sigma Aldrich.  
6.2.2 Nanoparticles preparation 
Standard emulsion method was used to prepare nanoparticles. Briefly, PLGA polymer was 
dissolved in ethyl acetate and emulsified with 1% PVA using probe sonicator. The emulsion 
was then stirred overnight until the solvent is evaporated. The particles were then centrifuged 
washed, and finally reconstituted in water and stored at 4°C until it is used. The particles were 
then surface coated with t Tf or HSA by using EDC/ NHS chemistry, using standard protocol. 
The amount of protein conjugated was then quantified using protein assay. Three different 
coating densities of Tf and HSA was achieved. For the Tf coated particles, the final 
concentrations of Tf in 5 mg/ml of PLGA particles were found to be of 3mg/ml (25 uM), or 30 
ug/ml (250 nM) or 60 ug/ml (500 nM). For the HSA coated particles, the final concentrations 
of HSA in 5 mg/ml of PLGA particles were found to be of 2.5 mg/ml (25 uM), or 25 ug/ml 
(250 nM) or 50 ug/ml (500 nM). 
6.2.3 ThT 
A 3.2 mg/ml concentration of ThT was dissolved in Tris buffer (pH 8). For free Tf and HSA 
inhibitory studies, 45 µM of Aβ (1-42) was aggregated with 5 or 10 µM of Tf or HSA for 24 
hours. For nanoparticle coated Tf samples, 20 µl of 19 µM Aβ (1-42) was added to 5 µl of PBS 
buffer for 2 hours. Then, NP (water was added instead of proteins) and NP/ Tf and NP/HSA 
with Tf or HSA concentrations of (5 µM, 50 nM, 100 nM) or 5 µM of free Tf or HSA were 
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added and aggregated for 24 hours at 37°C. Three independent experiments were performed, 
and ThT fluorescence was measured using Spectramax M3 spectrometer at 440/482 nm 
fluorescence endpoint. 
6.2.4 DLS 
The size of the aggregated samples was measured using a Malven zetasizer instrument in the 
lab. The same sample conditions used for the ThT measurements were used for the DLS study. 
Also, the size of NP, NP/ Tf, and NP/HSA, were measured for NP size characterization. Three 
independent size measurement experiments were performed. 
6.2.5 AFM 
HITACHI AFM 5100N in lab was used. The AFM tip (Nanosensors, CA) was used for the 
imaging. Images were performed in tapping mode, with force constant is 0.5-9.5 N/m, resonance 
frequency 45-115 KHz, average length is 225 µm, and the average width is 28 µm. Some of the 
ThT samples were sonicated and 1 µl of the solutions were spotted on mica. Then, the samples 
were imaged after drying. Also, nanoparticles were imaged using the tapping mode, and the size 
of the particles was determined. All sample conditions were imaged three times at a scan area of 
6x6 µm. 
6.2.6 Nanoparticle binding assay 
Samples were prepared to similar protocol used for the ThT measurements. Then the samples were 
centrifuged, and the supernatant were imaged by confocal microscope, to assess the abeta 
aggregation in solution. Confocal images were performed with Leica confocal microscope in the 
department (funded by NSF-MRI grant to Dr. Gargi Ghosh (PI)). 
 
 69 
 
6.3 Results and discussion 
First, we tested the ability of transferrin and human serum albumin on inhibiting abeta peptide 
aggregation. For that, we tested the aggregation of abeta peptide with and without t Tf and HSA 
by thioflavin assay. As can be seen from the tht measurements in Figure 6.1, the CSF proteins 
were able to inhibit the aggregation of abeta peptide. We further confirmed this by testing the 
aggregation size by DLS. In the presence of Tf or HSA, the aggregation was significantly reduced 
(Figure 6.2).  
 
 
 
 
 
 
 
 
 
Figure 6.1. Thioflavin-T fluorescence measurements of abeta peptide (45 μM) aggregation with and 
without Tf and HSA. The ThT measurements indicate the inhibitory potential of Tf and HSA. 
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Figure 6.2. DLS measurements show the size of abeta peptide (45 μM) aggregation with and without Tf 
and HSA (10 μM) concentrations.  
 
We then used nanotechnology to deliver Tf and HSA to test their ability to capture abeta in solution 
and to prevent aggregation. Nanoparticles have the ability to deliver the proteins with increased 
therapeutic efficacy compared to systemic delivery. Further, they can increase the circulation of 
the proteins in the blood. Moreover, the technology could be applied to capture abeta in the blood 
or in the brain parenchyma to reduce the monomeric and oligomeric abeta, and to prevent 
aggregation. First, we produced PLGA nanoparticles with around 200 nm using standard emulsion 
technique, and subsequently surface coated with and HSA proteins. We calculated the amount of 
the coating by protein assay. The nanoparticle size and morphology were characterized by TEM 
and DLS. Particles around 200 nm size were obtained. The coating of Tf and HSA did not 
significantly increase the size of the particles (Figure 6.3).  
 
 
Abeta 
Abeta + Tf (10 μM) 
Abeta + HSA (10 μM) 
Intensity (p.d.u.) 
Size (nm) 
 71 
 
 
 
 
 
 
 
 
 
Figure 6.3. Nanoparticle characterization (A) PLGA nanoparticle morphology observed by AFM. (B) 
Surface coating of PLGA nanoparticles with Tf or HSA, and size characterization by DLS. Scale bar 
500nm. 
 
We then tested the potential of the particles in abeta aggregation inhibition by thioflavin-T. We 
tested different Tf and HSA coating amounts on abeta aggregation. From the studies, we found 
that when coated with 100 nM of Tf and HSA, the aggregation of the abeta is inhibited (Figure 
6.4).  The aggregation inhibition was further studied with confocal microscopy, and AFM. Abeta 
aggregation was labeled with ThT, and the amount of abeta in the supernatant after 24 hours’ is 
observed by confocal microscopy. As can be seen from the images, the abeta alone samples 
increase the amount of ThT fluorescence in the supernatant compared to coated nanoparticles, 
indicating most of the abeta could be bound to Tf /HSA coated nanoparticles (Figure 6.5). The 
supernatant of nanoparticles showed less aggregated size, indicating inhibition. The AFM images 
corroborate the findings, where more bound abeta aggregates in the coated nanoparticles compared 
to nanoparticles alone where scattered aggregation can be observed (Figure 6.6).  
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Figure 6.4. Thioflavin-T fluorescence measurements of abeta peptide (15uM) aggregation with and 
without Tf and HSA coated nanoparticles. 
 
 
Figure 6.5. Confocal images of the supernatant of the abeta peptide aggregation with and without Tf and 
HSA coated NP. 
 
 
 
 
 
 
 
 
Figure 6.6. AFM images of abeta peptide aggregation with and without Tf and HSA coated nanoparticles 
ted nanoparticles. Scale bar 500 nm. 
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6.4 Conclusion 
In this chapter, we show that transferrin, and human serum albumin coated nanoparticles bind 
abeta, and significantly prevented abeta aggregation. Further, the amount of abeta in solution is 
significantly reduced in nanoparticles coated samples. Hence, nanoformulated cerebral proteins 
could be applied to reduce the amount of abeta in AD patients. Further, they could be further 
modified to successfully cross the blood barrier and capture the unwanted abeta in the brain, and 
could have potential as a nanotherapeutic approach for treating Alzheimer’s disease.  
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Chapter 7: Conclusion 
7.1. General Conclusions 
Although several studies have been reported on understanding the biomolecule cues associated 
with Alzheimer’s disease, the role of extracellular biomolecules in Alzheimer’s causing peptides 
aggregation and potential novel drug targets studied in this thesis, hasn’t been explored in detail. 
In this thesis study, the role of glycosaminoglycans, extracellular enzymes, and cerebral proteins 
in Alzheimer’s causing peptides abeta peptide, and tau peptide aggregation has been studied in 
detail. Thioflavin-T, TEM, AFM, DLS, and cellular characterization methods were used to study 
the aggregation process. The thesis study shows that glycosaminoglycans promote the aggregation 
and toxicity of tau peptides, and the effects could be mitigated by the application of cationic 
polymers, polyethyleneimine and polyarginine. Extracellular enzymes transglutaminase and lysyl 
oxidase on the other hand, promoted the aggregation and oxidative stress of abeta peptides, and 
small molecule osmolytes l-proline and betaine show potential in inhibiting the aggregation of the 
abeta peptides. In addition, the thesis study reveals that the abeta aggregation process could be 
inhibited by cerebral proteins transferrin, and human serum albumin nanoformulations.  
7.2. Future directions 
This thesis studies the role of biomolecule cues and their inhibition by potential drug candidates 
in detail. However, the mechanism of action of the inhibitory drugs on peptide aggregation in the 
presence of biomolecules has yet to be studied. Further, the major challenge in Alzheimer’s drug 
 76 
 
delivery is the blood brain barrier (BBB). Hence, the potential drug molecules identified in this 
thesis and in the literature could be nanoformulated to cross the BBB effectively, and target the 
affected region for effective drug delivery. The detailed characterization, and mechanism of action 
of the nanoformulation needs to be studied in vitro. Finally, the effective nanoformulations could 
be tested in vivo, in Alzheimer’s disease model to realize its effectiveness.   
 
 
 
 
 
 
 
 
